Tirzepatide Research Guide

Full name: Tirzepatide (Dual GIP/GLP-1 Receptor Agonist)

A dual GIP and GLP-1 receptor agonist approved as Mounjaro/Zepbound. Achieves up to 22.5% body weight loss, the highest of approved therapies.

How Tirzepatide Works

Activates both GIP and GLP-1 receptors simultaneously for synergistic effects on insulin secretion, appetite reduction, and fat metabolism. GIP activation enhances fat oxidation and energy expenditure.

Dosing Protocol

• Typical dose: 2.5 mg → titrate up to 15 mg
• Frequency: Once weekly
• Duration: Ongoing (chronic)
• Route: Subcutaneous injection

Reported Benefits

• Superior weight loss (20-25%)
• Excellent glycemic control
• Reduced triglycerides
• Lower blood pressure
• Improved insulin sensitivity
• Potential MASH benefits

Potential Side Effects

• Nausea (most common)
• Diarrhea
• Decreased appetite
• Vomiting
• Constipation
• Injection site reactions

Research Citations

1. SURMOUNT-1: Tirzepatide for weight management in obesity (2022) - Participants on 15mg lost 22.5% of body weight vs 2.4% placebo over 72 weeks.
2. SURPASS-4: Tirzepatide vs insulin glargine in T2DM (2022) - Tirzepatide demonstrated superior HbA1c reduction with 10-12kg weight loss advantage.

Related Weight Management Compounds

• AOD-9604 - Full Profile
• Semaglutide - Full Profile
• Retatrutide - Full Profile
• Tesofensine - Full Profile
• CagriSema - Full Profile
• Survodutide - Full Profile

View full Tirzepatide profile with 3D molecule viewer →